View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 11, 2017

Inotek closes enrolment in Phase II trial of trabodenoson + latanoprost for glaucoma

Inotek Pharmaceuticals has closed patient enrolment in the Phase II clinical trial of fixed-dose combination (FDC) of trabodenoson and latanoprost to treat patients with glaucoma.

Inotek Pharmaceuticals has closed patient enrolment in the Phase II clinical trial of fixed-dose combination (FDC) of trabodenoson and latanoprost to treat patients with glaucoma.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

Trabodenoson is a highly selective adenosine mimetic developed to increase the natural function of the trabecular meshwork for reducing the intraocular pressure (IOP)

The prostaglandin analog latanoprost is designed to target the secondary uveoscleral pathway.

The randomised, double-masked, dose-ranging Phase II trial enrolled around 200 patients.

The trial will evaluate the overall benefit / risk profile of the combination therapy given via binocular topical application to patients with ocular hypertension or primary open-angle glaucoma for eight weeks.

"We have completed active recruitment of glaucoma patients in our Phase II FDC trial."

Inotek president and chief executive officer David Southwell said: “We have completed active recruitment of glaucoma patients in our Phase II FDC trial.

“This is an important milestone as we continue to believe our FDC programme has the potential to address a larger market opportunity than monotherapy, and provide patients with a novel treatment option that includes two complementary eye pressure lowering mechanisms."

The trial will assess a combination of 6% trabodenoson and 0.005% latanoprost, 3% trabodenoson and 0.005% latanoprost, 6% trabodenoson with 0.0025% latanoprost, as well as individual doses of 0.005% latanoprost and 0.0025% latanoprost.

The trabodenoson doses were chosen to optimise IOP decrease and maintain the established tolerability and safety profile, while the selected latanoprost doses were based on efficacy and safety profiles of various doses.

It is expected that the top-line results from the Phase II FDC trial will be reported in July.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena